JPRN-UMIN000009032
Recruiting
Phase 2
PhaseII Study of Neoadjuvant and adjuvant Chemotherapy with Pemetrexed/Carboplatin/Bevacizumab in patients with non-squamouns non Small-cell lung cancer - PhaseII Study of Neoadjuvant and adjuvant Chemotherapy with Pemetrexed/Carboplatin/Bevacizumab in patients with non-squamouns non Small-cell lung cancer
Kansai Medical University Hirakata Hospital0 sites35 target enrollmentOctober 3, 2012
Conditionson-Squamouns Non-small-cell-lung-cancer
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- on-Squamouns Non-small-cell-lung-cancer
- Sponsor
- Kansai Medical University Hirakata Hospital
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •\>preoperative therapy (1\) severe comorbit disease (2\) history of hemoptysis, coagulation disorder and thrombosis or receive oral/i.v. hemostatic drug (3\) With a clinical bleeding tendency (4\) tumor cavitation and invasion to the major vessel (5\) Patients of Untreated fracture (Such as compression fractures due to osteoporosis are excluded) or High degree of wound (7\)Patients of the merger of infections requiring intravenous administration of anti\-viral agents or anti\-fungal agents,antibiotics (8\) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) (9\) Patients with uncontrollable gastrointestinal ulceration (10\) Patients with current or previous (within one year) history of gastrointestinal perforation (11\) Patients with Symptomatic congestive heart failure,Unstable angina,Arrhythmia with treatment. Patients With a history of myocardial infarction within one year prior to registration. (12\)In patients with persistent diarrhea. (There is a watery stool more than three times a day at the time of registration) (13\) Patients with previous histories of drug allergy (14\)history of drug induced interstitial pneumonia (15\)regnant or lactating women or those who declined contraception (16\)those judged to be not suitable by the attending physician \>postoperative therapy (1\) It is found that you have been registered in violation of the selection criteria or exclusion criteria (2\) Apparent worsening of the disease due to cancer was observed
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase II trial of Neoadjuvant and adjuvant chemotherapy with Gemcitabine and TS-1 combination for patients with locally advanced pancreatic cancerpancreatic cancerJPRN-UMIN000005578Chiba study group of adjuvant chemotherapy for pancreatic cancer45
Completed
Phase 2
A Phase II study of neoadjuvant combination chemotherapy with TS-1, cisplatin and Paclitaxel (PCS) for resectable advanced gastric cancer.resectable advanced gastric cancerJPRN-UMIN000006674Kinki University Faculty of Medicine20
Not Yet Recruiting
Phase 2
Phase II multicenter study of neoadjuvant chemotherapy with XELOX for locally advanced rectal cancerJPRN-UMIN000024357Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University35
Not Yet Recruiting
Phase 2
Multicenter phase II study of neoadjuvant chemotherapy of gemcitabine+nab-paclitaxel therapy for patients with resectable pancreatic cancer.Invasive ductal adenocarcinomaJPRN-UMIN000028101Division of Hepato-biliary-pancreatic Surgery Department of Surgery, Kobe University Graduate School of Medicine45
Active, Not Recruiting
Phase 1
Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectableon-small cell lung cancerMedDRA version: 20.0 Level: LLT Classification code 10029514 Term: Non-small cell lung cancer NOS System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004515-45-ESFundación GECP90